BioNTech SE - American Depositary Shares (NQ:BNTX)

BioNTech (BNTX) Q3 2025 Earnings Call Transcript

Topics Artificial Intelligence Intellectual Property

BioNTech (BNTX) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership.

Topics Earnings

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run ↗

November 13, 2025

Via Benzinga

BioNTech Says Collaboration With Pfizer Going Strong After Report Indicated US Pharma Giant Considering Stake Sale In The German Company ↗

November 13, 2025

A BioNTech spokesperson told Reuters that the two companies continue to have a “close and strong collaboration.”

Via Stocktwits

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Pfizer, BioNTech’s Updated COVID-19 Vaccine Shows Robust Immune Response In Late-Stage Study – More Details Inside ↗

September 08, 2025

Via Stocktwits

What Analysts Are Saying About BioNTech Stock ↗

September 08, 2025

Via Benzinga

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership ↗

November 03, 2025

BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost optimization.

Via Benzinga

BioNTech SE (NASDAQ:BNTX) Reports Mixed Q3 2025 Results with Major Revenue Beat and Quarterly Loss ↗

November 03, 2025

BioNTech Q3 2025: Revenue surges on a $1.5B partnership payment, but company posts a net loss. Full-year sales guidance was raised significantly.

Via Chartmill

Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers

October 27, 2025

As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the...

2 Unstoppable Dividend Stocks Yielding More Than 4% That Income-Seeking Investors Will Want to Buy in November and Hold Forever ↗

Topics Artificial Intelligence Economy Intellectual Property

October 25, 2025

Both companies are monsters in their industry and are poised to thrive.

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

Topics Government Intellectual Property World Trade

Beyond The Numbers: 7 Analysts Discuss BioNTech Stock ↗

October 10, 2025

Via Benzinga

October 08, 2025

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...

These biotechs could finally come into their own by the end of the decade.

Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead ↗

October 08, 2025

On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's...

Topics Government World Trade

Healthcare Sector Shines Amidst Market Turbulence, Bolstering S&P 500 Resilience

October 02, 2025

Decoding Life's Blueprint: New Tech Maps RNA-Protein Interactions, Unlocking Disease Cures

Topics Artificial Intelligence Economy Stocks

October 02, 2025

A monumental leap in biomedical research has been announced with the development of a breakthrough technology capable of mapping the entire intricate network of RNA-protein interactions within human...

The company's push deeper into a hot new technology, plus good news from a top collaborator, put the shine on its equity.

Topics Artificial Intelligence Derivatives

Why BioNTech Stock Jumped by Nearly 4% on Wednesday ↗

October 01, 2025

Investors were cheered by two pieces of good news concerning the biotech's most famous product.

Topics Artificial Intelligence Government World Trade

Why BioNTech Stock Bumped Higher Today ↗

September 22, 2025

Moderna stock toppled Friday after advisors to the CDC and Prevention ended the universal recommendation for Covid vaccines.

CDC Ends Universal Covid Vaccine Recommendation; Moderna Skids ↗

September 19, 2025

The Battle Over Covid Vaccines Hits A Fever Pitch As RFK-Picked Panel Makes Its Debut ↗

September 18, 2025

The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters.

Moderna's updated Spikevax shows strong antibody response and safety, targeting dominant COVID-19 variants like LP.8.1 in high-risk and older adults.

Topics Government

Moderna Reports 8-Fold Jump In Antibodies With Updated Spikevax ↗

September 16, 2025

Via Benzinga

Oracle Retreats, Fed Rate Cut Looms, and Vaccine Politics Shake Pharma Stocks ↗

September 15, 2025

Markets closed Friday in mixed fashion as economic uncertainty and politics clashed with earnings optimism. Oracle's rollercoaster continues, RFK Jr. rattles vaccine makers, and the Fed appears poised...

Via Chartmill

Topics Artificial Intelligence Economy

Synopsys, Chewy, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (Sep. 8- Sep. 12): Are The Others In Your Portfolio? ↗

September 14, 2025

Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biotech trial updates and mixed analyst calls pressured others.

Via Benzinga

Topics Earnings

Why BioNTech Stock Sank by More Than 7% Today ↗

September 12, 2025

The type of vaccine it's most famous for might be cast in a very unflattering light in the very near future..

Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths ↗

Topics Death Government

September 12, 2025

Shares of COVID-19 vaccine makers are trading lower Friday. Vaccine stocks fell Friday on a Washington Post report that Trump administration officials plan to link the shots to 25 child deaths.

Via Benzinga

Topics Government

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗

September 10, 2025

Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.

Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults ↗

Topics Government

September 08, 2025

Pfizer and BioNTech's LP.8.1 COVID-19 vaccine boosts antibodies 4-fold in high-risk adults, with no new safety concerns reported.

Via Benzinga

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy ↗

September 08, 2025

BioNTech and Bristol Myers report strong interim results for pumitamig plus chemo in lung cancer, showing high response rates.

Via Benzinga

Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch ↗

September 08, 2025

Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer.

The company might be close to commercializing its most advanced pipeline program.

Why BioNTech Stock Crushed the Market Today ↗

September 05, 2025